Skip to main content
. 2022 Aug 22;13:757480. doi: 10.3389/fimmu.2022.757480

Figure 6.

Figure 6

Proposed solutions to the side effects of anti-CD47 treatments. (A) antibody fusion proteins, e.g., TTI-621 (116) or ALX-148 (26); (B) “initiation doses” followed by “therapeutic doses”, e.g., Hu5F9-G4 (117); (C) pro-drug vesicle-induced immunogenic cell death combined with CD47 blockade (54); or (D) tumor-targeting nanoparticles loaded with anti-CD47 antibody (27).